Takeda considering options over US Actos court ruling
29 April 2013
Watson sues US FDA regarding generic Actos approval delay
16 August 2012
EC backs continued use of pioglitazone drugs for diabetes
10 January 2012
Takeda ends Daxas co-promotion with MSD; Actos law suits
3 January 2012
Merck & Co drops combo diabetes drug Janacti filing in Europe; presents data on discontinued vorapaxar study
15 November 2011
US FDA sets PUDFA date for Takeda diabetes drug alogliptin and fixed-dose alogliptin/pioglitazone
2 November 2011
Prior CHMP positive benefit-risk for pioglitazone confirmed; EMA starts NSAIDS review
24 October 2011
New twist in diabetes drugs could reduce life-threatening side effects
12 September 2011
Type 2 diabetes agents - DPP-IV inhibitors - will be main beneficiaries of pioglitazone problems
1 August 2011
Takeda refiles NDAs with US FDA for diabetes drug alogliptin and combo with pioglitazone
27 July 2011
EMA recommends Boehringer/Lilly’s Tradjenta, Novartis’ Votubia and Sigma-Tau’s Eurartesim; updates on pioglitazone
27 June 2011
Preliminary safety data relating to bladder cancer risk of Takeda’s Actos under review by US FDA; Actelion subpoenaed over Tracleer marketing
20 September 2010
New study finds little difference in cardiac risk for GlaxoSmithKline’s Avandia and Takeda’s Actos
25 August 2010
Takeda files NDA for azilsartan medoxomil in USA, settles Actos patent disputes; Actavis debuts generic Flomax
29 April 2010
Big pharma struggles to benefit from increased CVD drug usage in market set to grow to $107 billion in 2018
3 March 2010
Takeda’s 3rd quarter profits hit by in-licensing costs and sales declines for Actos and Prevacid
4 February 2010
Takeda gets rights to Seattle’s brentuximab and picks Pfizer for Actos in China; and Amgen licenses diabetes drug
15 December 2009
Japanese drug majors deliver mixed first-half results
2 November 2009
Takeda sets up new subsidiaries to expand its operations in Mexico, Turkey and five other countries in Europe
1 October 2009
Takeda gets FDA Complete Response letter for fixed-dose alogliptin and Actos for type 2 diabetes
7 September 2009
Japan stock market week to June 8, 2009
9 June 2009
Record sales balanced by costs for Takeda
27 May 2009
Japan stock market week to May 11, 2009
12 May 2009
Takeda in Portugal
8 May 2009
Japan stock market week to April 20, 2009
21 April 2009
Amylin narrows 1st-qtr loss 34% to $47M
20 April 2009
Additional Actos indication for Takeda
30 March 2009
Takeda recovers UK Prostap rights from Wyeth
30 March 2009
Japan stock market week to Mar 9, 2009
16 March 2009
Japan stock market week to Feb 9, 2009
16 February 2009
Japan stock market week to Jan 19, 2009
26 January 2009
Japan stock market week to Jan 12, 2009
19 January 2009
Japan stock market week to Jan 5, 2009
12 January 2009
Japan stock market week to Dec 15, 2008
22 December 2008
Japan stock market week to Dec 1, 2008
8 December 2008
Takeda and Lilly breach ABPI Code of Practice
8 December 2008
Japan stock market week to Nov 10, 2008
17 November 2008
Takeda's recurring profit down 70%
10 November 2008
Alogliptin delayed due to lack of FDA resources
20 October 2008
Japan stock market week to Oct 6, 2008
13 October 2008
Japan stock market week to Sept 29, 2008
6 October 2008
Takeda files alogliptinand Actos NDA in USA
29 September 2008
Japan stock market week to Sept 8, 2008
15 September 2008
Japan stock market week to August 4, 2008
11 August 2008
UPDATE: FDA panel votes in favor of outcomes over surrogate markers in diabetes drug approval
7 July 2008
Tokyo stocks to May 12, 2008
19 May 2008
Japan stock market week to April 14, 2008
21 April 2008
UK complaint against Actos ad upheld
14 April 2008
Japan stock market week to April 7, 2008
14 April 2008
Actos cuts atherosclerosis in type 2 diabetics
7 April 2008
Japan stock market week to March 24, 2008
31 March 2008
Japan stock market week to February 4 , 2008
14 February 2008
Amgen sells Takeda Japanese rights to 13 drugs in a deal that could be worth up to $1.2B
11 February 2008
EMEA seeks expanded rosiglitazone warning
4 February 2008
Takeda set for $18.5B sales 2015, R&I says
28 January 2008
Japan stock market week toJan 14, 2008
21 January 2008
Daiichi Sankyo and Eli Lilly submit NDA to US FDA for prasugrel; to be sold as Effient
14 January 2008
GSK defends Avandia against findings of CV risk by ICES group
17 December 2007
Jordan's Hikma to buy APM for $164M
17 December 2007
Japan stock market week to Nov 26, 2007
3 December 2007
Takeda ads to promote Actos' lack of cardio risks
26 November 2007
Japan stock market week to Nov 12, 2007
19 November 2007
FDA orders GSK to add warning to Avandia
19 November 2007
Takeda's income for fiscal 1st half grows 37%
19 November 2007
Japan stock market week to Oct 29, 2007
5 November 2007
Correction to Actos article
5 November 2007
EMEA: Avandia/Actos benefits outweigh risks
29 October 2007
Latest JAMA findings slam Avandia CV safety
17 September 2007
Japan stock market week to August 27, 2007
3 September 2007
TZD diabetes drugs to get black box warning
20 August 2007
Japan stock market week to August 6, 2007
13 August 2007
Dosing initiated in Ph III balaglitazone trial
6 August 2007
Japan stock market week to July 30, 2007
6 August 2007
Japan stock market week to July 9, 2007
26 July 2007
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
